Literature DB >> 10388977

Type 2 diabetes: incremental medical care costs during the first 8 years after diagnosis.

J B Brown1, G A Nichols, H S Glauber, A W Bakst.   

Abstract

OBJECTIVE: To describe and analyze the time course of medical care costs caused by type 2 diabetes, from the time of diagnosis through the first 8 postdiagnostic years. RESEARCH DESIGN AND METHODS: From electronic health maintenance organization (HMO) records, we ascertained the ongoing medical care costs for all members with type 2 diabetes who were newly diagnosed between 1988 and 1995. To isolate incremental costs (costs caused by the diagnosis of diabetes), we subtracted the costs of individually matched HMO members without diabetes from costs of members with diabetes.
RESULTS: The economic burden of diabetes is immediately apparent from the time of diagnosis. In year 1, total medical costs were 2.1 times higher for patients with diabetes compared with those without diabetes. Diabetes-associated incremental costs (type 2 diabetic costs minus matched costs for people without diabetes) averaged $2,257 per type 2 diabetic patient per year during the first 8 postdiagnostic years. Annual incremental costs varied relatively little over the period but were higher during years 1, 7, and 8 because of higher-cost hospitalizations for causes other than diabetes or its complications.
CONCLUSIONS: For the first 8 years after diabetes diagnosis, patients with type 2 diabetes incurred substantially higher costs than matched nondiabetic patients, but those high costs remained largely flat. Once the growth in costs due to general aging is controlled for, it appears that diabetic complications do not increase incremental costs as early as is commonly believed. Additional research is needed to better understand how diabetes and its diagnosis affect medical care costs over longer periods of time.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10388977     DOI: 10.2337/diacare.22.7.1116

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  35 in total

1.  The cost burden of diabetes mellitus: the evidence from Germany--the CoDiM study.

Authors:  I Köster; L von Ferber; P Ihle; I Schubert; H Hauner
Journal:  Diabetologia       Date:  2006-05-11       Impact factor: 10.122

2.  Health Care Costs Associated With Macrovascular, Microvascular, and Metabolic Complications of Type 2 Diabetes Across Time: Estimates From a Population-Based Cohort of More Than 0.8 Million Individuals With Up to 15 Years of Follow-up.

Authors:  Hsuan-Ying Chen; Shihchen Kuo; Pei-Fang Su; Jin-Shang Wu; Huang-Tz Ou
Journal:  Diabetes Care       Date:  2020-05-22       Impact factor: 19.112

3.  [Costs involved in the early and late phases of diabetes mellitus].

Authors:  A Liebl
Journal:  Internist (Berl)       Date:  2007-07       Impact factor: 0.743

4.  Examining the economic costs related to lifestyle and pharmacological interventions in youth with Type 2 diabetes.

Authors:  Thomas Songer; Judith Glazner; Laura P Coombs; Leona Cuttler; Mary Daniel; Silvia Estrada; Georgeanna Klingensmith; Andrea Kriska; Lori Laffel; Ping Zhang
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2006-06-01       Impact factor: 2.217

5.  Trajectory of Excess Medical Expenditures 10 Years Before and After Diabetes Diagnosis Among U.S. Adults Aged 25-64 Years, 2001-2013.

Authors:  Sundar S Shrestha; Ping Zhang; Israel A Hora; Edward W Gregg
Journal:  Diabetes Care       Date:  2018-11-19       Impact factor: 19.112

6.  Screening adults for pre-diabetes and diabetes may be cost-saving.

Authors:  Ranee Chatterjee; K M Venkat Narayan; Joseph Lipscomb; Lawrence S Phillips
Journal:  Diabetes Care       Date:  2010-07       Impact factor: 17.152

7.  Factors affecting costs and utilization of type 2 diabetes healthcare: a cross-sectional survey among 15 hospitals in urban China.

Authors:  Weibing Wang; Chaowei Fu; Haijing Zhuo; Jianfeng Luo; Biao Xu
Journal:  BMC Health Serv Res       Date:  2010-08-20       Impact factor: 2.655

8.  Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes.

Authors: 
Journal:  Diabetes Care       Date:  2003-09       Impact factor: 19.112

Review 9.  The economics of screening and treatment in type 2 diabetes mellitus.

Authors:  Maria Raikou; Alistair McGuire
Journal:  Pharmacoeconomics       Date:  2003       Impact factor: 4.981

10.  Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.

Authors:  Robert J Straka; Larry Z Liu; Prafulla S Girase; Allyson DeLorenzo; Richard H Chapman
Journal:  Cardiovasc Diabetol       Date:  2009-09-26       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.